A randomized phase II study of pivanex and docetaxel compared to docetaxel monotherapy in patients with previously treated advanced NSCLC

被引：1
|
作者：
Raghunadharao, D
Koralewski, P
Serwatowski, P
Gruszfeld, A
Lakshmaiah, K
Szczesna, A
Savin, M
Yen, K
Bhatnagar, A
Green, M
机构：
[1] Nizams Inst Med Sci, Hyderabad, Andhra Pradesh, India
[2] Szpital Specjalistyczny Rydygiera, Krakow, Poland
[3] Szpital Specjalistyczny Alfreda, Szczecin, Poland
[4] Warminsko Mazurskie Ctr Onkol, Olsztyn, Poland
[5] Kidwai Mem Inst Oncol, Bangalore, Karnataka, India
[6] Mazawieckie Ctr Leczenia, Otwock, Poland
[7] Texas Canc Ctr Med City, Dallas, TX USA
[8] Tita Pharmaceut Inc, San Francisco, CA USA
[9] Med Univ S Carolina, Charleston, SC 29425 USA
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
10.1016/S0169-5002(05)81053-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S265 / S265
页数：1
相关论文
共 50 条
  • [21] A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer
    Sym, Sun Jin
    Chang, Heung Moon
    Kang, Hye Jin
    Lee, Sung Sook
    Ryu, Min-Hee
    Lee, Jae-Lyun
    Kim, Tae-Won
    Yook, Jeong Hwan
    Oh, Sung Tae
    Kim, Byung Sik
    Kang, Yoon-Koo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 63 (01) : 1 - 8
  • [22] A phase II study of the effectiveness of docetaxel (Taxotere) in women with advanced breast cancer previously treated with polychemotherapy
    C. G. Alexopoulos
    G. Rigatos
    A. P. Efremidis
    A. Papacharalambous
    A. Alexopoulos
    M. Vassilomanolakis
    E. Patila
    Cancer Chemotherapy and Pharmacology, 1999, 44 : 253 - 258
  • [23] A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in pts with NSCLC previously treated with platinum-based chemotherapy: Results of Okayama Lung Cancer Study Group (OLCSG) trial 0503
    Segawa, Y.
    Hotta, K.
    Takigawa, N.
    Matsuo, K.
    Yoshioka, H.
    Hayashi, H.
    Nogami, N.
    Tabata, M.
    Kiura, K.
    Tanimoto, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [24] A phase II study of the effectiveness of docetaxel (Taxotere) in women with advanced breast cancer previously treated with polychemotherapy
    Alexopoulos, CG
    Rigatos, G
    Efremidis, AP
    Papacharalambous, A
    Alexopoulos, A
    Vassilomanolakis, M
    Patila, E
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 44 (03) : 253 - 258
  • [25] Phase II study of docetaxel and celecoxib as first or second line therapy in patients with advanced NSCLC
    Underhill, C
    Hui, R
    Links, M
    Hawson, G
    Chern, B
    Yip, D
    Blackwell, T
    Crombie, C
    Boyer, M
    LUNG CANCER, 2005, 49 : S272 - S273
  • [26] Efficacy of radiotherapy combined with atezolizumab or docetaxel in patients with previously treated NSCLC
    Xu, Junzhu
    Wang, Haitao
    Zhang, Chi
    Jin, Su-Han
    Chen, Xiaofei
    Tan, Fangya
    Frey, Benjamin
    Hecht, Markus
    Sun, Jian-Guo
    Gaipl, Udo S.
    Mu, Hu
    Zhou, Jian-Guo
    ISCIENCE, 2024, 27 (12)
  • [27] Phase II randomized clinical trial comparing albumin-bound docetaxel vs. docetaxel in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.
    Wang, Zhiqiang
    Chen, Dongliang
    Li, Hongli
    Yang, Mudan
    Lin, Rongbo
    Cheng, Ying
    Li, Zhiwei
    Huang, Xiwen
    Wang, Wei
    Li, Hui
    Liu, Hao
    Dai, Youguo
    Wang, Jufeng
    Zhao, Xin
    Yang, Yan
    Qu, Xiujuan
    Zhao, Jun
    Zhang, Zhe
    Zeng, Yanyan
    Xu, Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] Effect of nanosomal docetaxel lipid suspension (NDES) on response rate compared to docetaxel: A randomized phase II study in patients with locally advanced or metastatic breast cancer
    Ahmad, Ateeq
    Sheikh, Saifuddin
    Taran, Rakesh
    Srivastav, Shanti P.
    Prasad, Krishna
    Rajappa, Senthill J.
    Kumar, Vijay
    Gopichand, M.
    Paithankar, Mahesh
    Sharma, Manish
    Rane, R. C.
    Ahmad, Imran
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial
    Zhou, Caicun
    Huang, Dingzhi
    Fan, Yun
    Yu, Xinmin
    Liu, Yunpeng
    Shu, Yongqian
    Ma, Zhiyong
    Wang, Ziping
    Cheng, Ying
    Wang, Jie
    Hu, Sheng
    Liu, Zhihua
    Poddubskaya, Elena
    Disel, Umut
    Akopov, Andrey
    Dvorkin, Mikhail
    Zheng, Wenjuan
    Ma, Yiyuan
    Wang, Yan
    Li, Songzi
    Yu, Cunjing
    Rivalland, Gareth
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (01) : 93 - 105
  • [30] KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC
    Ren, Shengxiang
    Feng, Jifeng
    Ma, Shenglin
    Chen, HuaJun
    Ma, Zhiyong
    Huang, Cheng
    Zhang, Li
    He, Jianxing
    Wang, Changli
    Zhou, Jianying
    Danchaivijtr, Pongwut
    Wang, Chin-Chou
    Vynnychenko, Ihor
    Wang, Kai
    Orlandi, Francisco
    Sriuranpong, Virote
    Li, Ben
    Ge, Jun
    Dang, Thao
    Zhou, Caicun
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (03) : 623 - 634
12345